Health Condition 1: null- All patients with newly diagnosed /relapsed AML who undergo induction or salvage chemotherapy and receive antifungal prophylaxis will be included in the study.
Conditions
Interventions
Intervention1: NOT APPLICABLE: NOT APPLICABLE
Control Intervention1: NOT APPLICABLE: NOT APPLICABLE
Sponsors
MSD PHARMA
Eligibility
Inclusion criteria
Inclusion criteria: a) Patients with newly diagnosed / relapsed AML (Both adult and pediatric patients); if they had or were anticipated to have neutropenia, with an absolute neutrophil count of 500 cells per cubic millimeter or less, for 7 days or more, resulting from remission-induction chemotherapy for newly diagnosed, or the first relapse of AML b) Willing to sign informed consent
Exclusion criteria
Exclusion criteria: a)Use of chemotherapy other than those mentioned. b)Invasive fungal infection within the previous 6 months, c)Clinically significant hepatic or renal dysfunction which precludes use of antifungal prophylaxis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome studied would be the incidence of fungal infections in patients undergoing chemotherapy for AML.Timepoint: 4 WEEKS | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes would include the use of prophylaxis, mortality associated with fungal infections and adverse events associated with the use of antifungal drugs.Timepoint: 4 WEEKS | — |
Countries
India
Contacts
Public ContactDr Biju George
Christian Medical College, Vellore
Outcome results
None listed